MYCN
Reaktivität: Human
WB
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal dilution of the MYCN antibody should be determined by the researcher.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Konservierungsmittel
Azide free
Lagerung
-20 °C
Informationen zur Lagerung
Aliquot the MYCN antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Target
MYCN
(N-Myc Proto-Oncogene Protein (MYCN))
Andere Bezeichnung
MYCN
Hintergrund
The v-Myc oncogene, initially identified in the MC29 avian retrovirus, causes myelocytomas, carcinomas, sarcomas and lymphomas, and belongs to a family of oncogenes conserved throughout evolution. In humans, the family consists of five genes: c-Myc, N-Myc, R-Myc, L-Myc and B-Myc. Amplification of the N-Myc gene has been found in human neuroblastomas and cell lines. Its amplification correlates well with the stage of neuroblastoma disease. Immunological studies have shown that the human N-Myc gene encodes a nuclear phosphoprotein that exhibits relatively short (30 min) half life in vivo. The prototype member of the family, c-Myc p67, binds DNA in a sequence-specific manner subsequent to dimerization with a second basic region helix-loop-helix leucine zipper motif protein, designated Max.